- Home
- BLZE vs TVRD Comparison
BLZE vs TVRD Comparison
Compare BLZE & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLZE
- TVRD
- Stock Information
- Founded
- BLZE 2007
- TVRD 2017
- Country
- BLZE United States
- TVRD United States
- Employees
- BLZE N/A
- TVRD N/A
- Industry
- BLZE Computer Software: Prepackaged Software
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- BLZE Technology
- TVRD Health Care
- Exchange
- BLZE Nasdaq
- TVRD Nasdaq
- Market Cap
- BLZE 300.7M
- TVRD 246.5M
- IPO Year
- BLZE 2021
- TVRD N/A
- Fundamental
- Price
- BLZE $9.45
- TVRD $33.88
- Analyst Decision
- BLZE Strong Buy
- TVRD Strong Buy
- Analyst Count
- BLZE 7
- TVRD 5
- Target Price
- BLZE $10.21
- TVRD $59.20
- AVG Volume (30 Days)
- BLZE 749.1K
- TVRD 21.2K
- Earning Date
- BLZE 11-06-2025
- TVRD 08-14-2025
- Dividend Yield
- BLZE N/A
- TVRD N/A
- EPS Growth
- BLZE N/A
- TVRD N/A
- EPS
- BLZE N/A
- TVRD N/A
- Revenue
- BLZE $137,286,000.00
- TVRD N/A
- Revenue This Year
- BLZE $16.78
- TVRD N/A
- Revenue Next Year
- BLZE $13.98
- TVRD N/A
- P/E Ratio
- BLZE N/A
- TVRD N/A
- Revenue Growth
- BLZE 19.08
- TVRD N/A
- 52 Week Low
- BLZE $3.94
- TVRD $8.13
- 52 Week High
- BLZE $9.92
- TVRD $36.71
- Technical
- Relative Strength Index (RSI)
- BLZE 74.51
- TVRD 66.16
- Support Level
- BLZE $7.91
- TVRD $29.33
- Resistance Level
- BLZE $9.92
- TVRD $31.88
- Average True Range (ATR)
- BLZE 0.41
- TVRD 2.09
- MACD
- BLZE 0.05
- TVRD 0.49
- Stochastic Oscillator
- BLZE 76.69
- TVRD 69.21
About BLZE Backblaze Inc.
Backblaze Inc provides cloud storage services. The company offers services such as Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. It is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases including backups, multi-cloud, application development, and ransomware protection and Backblaze Computer Backup automatically backs up data from laptops and desktops for businesses and individuals. Geographically, it derives a majority of revenue from the United States and the rest from the United Kingdom, Canada, and Other regions.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.